Posted by
Aaron Silletto on Saturday, May 31, 2008 12:02:37 PM
I saw an interesting editorial in today's edition of The Wall Street Journal Online, and I thought it noteworthy. Apparently, the Vioxx litigation is far from over. This editorial touches on two reversals of tort verdicts against the manufacturer of Vioxx, and sets those appeals in the context of the pending preemption litigation now before the U.S. Supreme Court. It is a short, but good, read for those of you who like to keep up on current trends in mass-tort litigation.
Texas and New Jersey may have different political cultures, but appeals courts in both states this week delivered a one-two punch to the liability suits against Merck for its Vioxx painkiller. In Texas, a court overturned a $26 million 2005 jury verdict against the drug company, while New Jersey's court whittled down an earlier verdict to exonerate Merck from a finding of consumer fraud and eliminate punitive damages.
***
(To read the entire article, click on the headline, above.)